
Sign up to save your podcasts
Or


We love to hear from our listeners. Send us a message.
Dr. Peter Marks, Director of the Center for Biologics Evaluation and Research (CBER) within the Food and Drug Administration (FDA) sits down with Cell & Gene: The Podcast host Erin Harris to discuss the most anticipated areas of innovation in clinical development, and he offers recommendations to companies in their engagement with the FDA in order to make manufacturing more streamlined and cost effective. Dr. Marks also provides advice to listeners about how and when to engage with CBER, and much more.
Subscribe to the podcast!
Apple | Spotify | YouTube
Visit my website: Cell & Gene
Connect with me on LinkedIn
By Erin Harris4.9
3838 ratings
We love to hear from our listeners. Send us a message.
Dr. Peter Marks, Director of the Center for Biologics Evaluation and Research (CBER) within the Food and Drug Administration (FDA) sits down with Cell & Gene: The Podcast host Erin Harris to discuss the most anticipated areas of innovation in clinical development, and he offers recommendations to companies in their engagement with the FDA in order to make manufacturing more streamlined and cost effective. Dr. Marks also provides advice to listeners about how and when to engage with CBER, and much more.
Subscribe to the podcast!
Apple | Spotify | YouTube
Visit my website: Cell & Gene
Connect with me on LinkedIn

3,447 Listeners

756 Listeners

154 Listeners

818 Listeners

113,121 Listeners

10,331 Listeners

337 Listeners

6,592 Listeners

5,610 Listeners

6,462 Listeners

85 Listeners

5,576 Listeners

11,013 Listeners

16 Listeners

1,480 Listeners